Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a report issued on Saturday.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.43.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $7.00 on Friday. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72. The stock has a market capitalization of $381.71 million, a price-to-earnings ratio of 25.00 and a beta of 0.89. The company has a 50-day simple moving average of $6.57 and a 200-day simple moving average of $7.56.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.20. The firm had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. During the same period in the prior year, the business earned ($0.51) EPS. As a group, research analysts forecast that Voyager Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after buying an additional 702,030 shares during the last quarter. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the second quarter valued at approximately $12,668,000. Armistice Capital LLC grew its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the period. Price T Rowe Associates Inc. MD increased its position in Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after purchasing an additional 37,144 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Voyager Therapeutics by 2.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after purchasing an additional 2,030 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.